Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why [Yahoo! Finance]
Sutro Biopharma, Inc. (STRO)
Last sutro biopharma, inc. earnings: 11/8 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
development platforms to treat several oncology indications. The company's pipeline comprises only one candidate, luveltamab tazevibulin or luvelta (formerly known as STRO-002), which is being developed for various FRa-expressing cancers. Sutro Biopharma's shares gained 8.9% in the past week after the company announced that it has begun enrollment in its global phase II REFRaME-L1 study of luvelta for patients with non-small cell lung cancer (NSCLC) whose tumor expresses FRa. Management claims that luvelta is differentiated from currently available treatment options for the above indication due to its precise design, wide therapeutic window and ability to treat patients with lower FRa expression profiles, offering patients a chance for targeted therapy. Year to date, shares of Sutro Biopharma have gained 16.8% compared with the industry's 1.4% growth. Image Source: Zacks Investment Research The planned REFRaME-L1 study will evaluate the safety and efficacy of luvelta in adul
Show less
Read more
Impact Snapshot
Event Time:
STRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STRO alerts
High impacting Sutro Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
STRO
News
- Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewswire
- Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC ConferenceGlobeNewswire
STRO
Earnings
- 11/13/24 - Beat
STRO
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/13/24 - Form 10-Q
- STRO's page on the SEC website